Company intelligence
As of September 24, 2026, Precision Neuroscience was last valued at ~$1B (September 2026 Series D) and has raised at least $250M in equity across 1 sourced funding round.
Precision Neuroscience develops a minimally invasive, high-resolution brain-computer interface (the Layer 7 Cortical Interface); it closed a $250M Series D in September 2026 at about a $1B valuation, co-led by Pershing Square and the newly formed Ackman Oxman Institute, the institute's first investment.
Is something wrong on this page?
Precision Neuroscience is a biotech company, based in New York, New York, USA, founded 2021.
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2026 | Series D | $250M | ~$1Bpost-money | Pershing SquareunverifiedAckman Oxman Instituteunverified WithDuquesne Family OfficeunverifiedB CapitalARK InvestInvusMubadala CapitalMirae Asset CapitalKorea Investment PartnersHitachi VenturesJSL Health Capital | GlobeNewswire |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
OpenEvidence, Precision Neuroscience and Rightway alone pulled in more than $655 million in late-September rounds, underscoring how much AI capital is now flowing into healthcare specifically.
Precision Neuroscience raised $250 million to advance its brain-computer interface technology, backed by Bill Ackman's Pershing Square and the Ackman Oxman Institute.
Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square and his new Ackman Oxman Institute, valuing the brain-computer interface company at just over $1 billion.
Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square, valuing the brain-computer interface company at just over $1 billion as it scales past 100 patient procedures.
Precision Neuroscience was last valued at ~$1B in its September 2026 Series D, according to GlobeNewswire (September 24, 2026).
Precision Neuroscience has raised at least $250M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $250M Series D in September 2026 at a ~$1B post-money valuation, reported by GlobeNewswire. Debt financing, tender offers and secondary sales are not counted.
Lead investors in Precision Neuroscience's sourced funding rounds include Pershing Square and Ackman Oxman Institute. Per round: its September 2026 Series D was led by Pershing Square and Ackman Oxman Institute.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.